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TROMBOTEK Study Group (by the site’s number)
1. Department of EmergencyMedicine, Istanbul Univer-
sity, Istanbul School of Medicine, Istanbul—Prof Me-
hmet Kurtoglu, MD, Principal Investigator (PI) and
Study Coordinator; Assoc Prof Murat Aksoy, MD;
Assoc Prof Hakan Yanar, MD.
2. Department of General Surgery, S¸is¸li Etfal Training
and Research Hospital, Istanbul—Prof Mehmet Mih-
manlı, MD (PI); Uygar Demir, MD.
3. Department ofCardiovascular Surgery, YuzuncuYilUni-
versity School of Medicine, Van—Assoc Prof Ekim
Hasan,MD(PI); Assoc Prof Veysel Kutay,MD(previous
PI); Yasin Melek, MD; Sedat Ozcan, MD.
4. Department of Cardiovascular Surgery, Uludag Univer-
sity, School of Medicine, Bursa—Assoc Prof Davit Saba,
MD (PI); Tolga Onder, MD; Dudu Aygun, MD;Murat
Bicer, MD; Kadir Ercan, MD; Arzu Gundogdu, MD.
5. Department of General Surgery, Ankara University
School of Medicine, Ankara—Prof Cuneyt Koksoy, MD
(PI); Rojbin Karakoyun, MD; Tuba Solak, Radiology
Technician; Elcin Arslan, Radiology Technician.
6. Department of Cardiovascular Surgery, Atatürk Univer-
sity School of Medicine, Erzurum—Prof Münacettin
Ceviz, MD (PI); Assoc Prof Necip Becit, MD; Yas¸ar
Karaca, MD.
7. Department of Cardiovascular Surgery, Dicle University
School ofMedicine, Diyarbakır—Prof Nesimi Eren,MD
(PI); Ferit Özdemir, MD; I˙lker Zan, MD.
were excellent, with a 3.3% VTE recurrence rate, 0.4% pulmonary8. Department of Cardiovascular Surgery, Ege University
School of Medicine, Izmir—Prof Emin Alp Alayunt,
MD (PI); Assoc Prof Yüksel Atay, MD; Serkan Ertu-
gay, MD.
9. Department of Cardiovascular Surgery, Erciyes Uni-
versity School of Medicine, Kayseri—Prof Yigit Ak-
cali, MD (PI); Hakan Ceryan, MD; Vural Polat,
MD; Cemal Kahraman, MD; Nuri Erdogan, MD,
Radiologist (discontinued); Guven Kahriman, MD,
Radiologist (discontinued); Ibrahim Sacit Tuna,
MD, Radiologist.
10. Department of Cardiovascular Surgery, Selcuk Uni-
versity Meram School of Medicine, Konya—Assoc
Prof Niyazi Gormus, MD (PI); Omer Tanyeli, MD.
11. Department of Cardiovascular Surgery, Dokuz Eylul
University School of Medicine, Izmir—Assoc Prof
Ozalp Karabay, MD (PI); Aycan Kavala, MD.
12. Department of Cardiovascular Surgery, Siyami Ersek
Chest, Heart and Vascular Surgery Training and Re-
search Hospital, Istanbul—Ugur Filizcan, MD (PI);
Bayer Cinar, MD (previous PI); Deniz Ozsoy, MD;
Cenk Aslan, MD.
13. Department of Cardiovascular Surgery, Baskent
University School of Medicine Ankara—Assoc Prof
Erdal Aslim, MD (PI); Assoc Prof Tankut Atay, MD.
14. Department of Cardiovascular Surgery, Diskapi
Training and Research Hospital, Ankara—Alp Dol-
gun, MD (PI); Tolga Soyal, MD (co-PI); Gokhan
Gokarslan, MD (previous PI); Muhammed Boz-
guney, MD; Zeki Temizturk, MD; Sahin Sahinalp,
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Much high-quality evidence exists for the effective therapy
for acute deep vein thrombosis (DVT); namely, rapid and therapeutic
low-molecular-weight heparin (LMWH) anticoagulation, followed
by transition to a vitamin K antagonist, early application of compres-
sion therapy, and ambulation. Moreover, markers for ceasing or
continuing oral anticoagulation are now coming to light, such as
D-dimer and follow-up duplex ultrasound imaging.1 The trials for
which the data are based on have generally captured early efficacy and
safety, such as recurrent venous thromboembolism (VTE), bleeding
rates, and tolerance. Fewer studies have captured the long-term results
of the evidence-based therapies for DVT, but these data are needed,
given the commonality of DVT occurrence and its primary nonfatal
sequelae, post thrombotic syndrome (PTS).
The current study by Kurtoglu et al is novel and important,
not because it confirms that LMWH transitioning to a vitamin K
antagonist is safe and effective but rather because it brings to light
that well-applied, comprehensive, multimodality therapy is highly
effective for preventing VTE recurrence and preventing major post
thrombotic morbidity. Unlike many trials that evaluate a single
variable intervention, this trial evaluated the “whole package” of
evidence-based DVT treatment, with excellent patient follow-up.
This trial mimics, in part, several studies showing efficacy of
multimodality intensive diabetes therapy, although there was no
separate control group in the current study. The primary outcomesembolism rate, and 0.7% venous ulceration at 18 months. Safety
was also excellent, with a major bleeding rate of 1.6% and an
adverse event rate of about 10%. Both of these measures rival prior
larger trial end point efficacy. Not examined here is the likely cost
savings resulting from outpatient treatment as the primary mode,
thus eliminating the need for laboratory draws (activated partial
thromboplastin time) and an inpatient stay.
A primary risk for PTS is recurrent DVT and a greater extent of
DVT. Although the incidence of C4 through C6 disease (more
severe PTS) was low in this study, it should be known that the best
measure for PTS is the Villalta score, and thus this study may
underestimate some of the disability related to the patient’s DVT.2
Regardless, the low rate of PTS may be because therapeutic anti-
coagulation compliance rates were high (80%), and those pa-
tients with an unprovoked DVT were very low; both of these
factors are associated with increased risk of PTS.3 Nonetheless, the
large number of patients in this study with an iliofemoral DVT, a
significant risk factor for PTS, underscores the effectiveness of this
multimodality therapy; that is, most of these iliofemoral segments
recanalized over time. As stated by the authors, these findings
challenge the wide application of expensive and invasive pharma-
comechanical therapy for all DVT patients. Similarly, Hull et al4
recently reported that prolonged LMWH therapy was associated
with a significant reduction in PTS compared with standard anti-
coagulation.
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rently available to manage acute DVT patients with excellent early
and long-term outcomes. As with so many other diseases, systems
to ensure comprehensive treatment for a disease from start to finish
are critical and should be an area of national health care priority.
The gap in so many of these diseases is not the tools, but the
consistent application of these tools in a timely and appropriate
manner.
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